^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    BLK (BLK proto-oncogene, Src family tyrosine kinase)

    i
    Other names: BLK, BLK Proto-Oncogene, Src Family Tyrosine Kinase, Tyrosine-Protein Kinase Blk, B Lymphoid Tyrosine Kinase, B Lymphocyte Kinase, MGC10442, P55-Blk, BLK Nonreceptor Tyrosine Kinase, MODY11
    3ms
    Integrating single-cell biophysical and transcriptomic features to resolve functional heterogeneity in mantle cell lymphoma. (PubMed, Sci Adv)
    In addition, changes in cell buoyant mass within primary patient specimens ex vivo correlate with sensitivity to Bruton's tyrosine kinase inhibitors in vivo in MCL and chronic lymphocytic leukemia, another B cell malignancy. These findings highlight the value of biophysical properties as biomarkers of response in pursuit of future precision therapeutic strategies.
    Journal
    |
    CD79A (CD79a Molecule) • BLK (BLK proto-oncogene, Src family tyrosine kinase)
    9ms
    Integrating Single-Cell Biophysical and Transcriptomic Features to Resolve Functional Heterogeneity in Mantle Cell Lymphoma. (PubMed, bioRxiv)
    Additionally, changes in cell buoyant mass within primary patient specimens ex vivo correlate with sensitivity to Bruton's Tyrosine Kinase inhibitors in vivo in MCL and chronic lymphocytic leukemia, another B-cell malignancy. These findings highlight the value of biophysical properties as biomarkers of response in pursuit of future precision therapeutic strategies.
    Journal
    |
    CD79A (CD79a Molecule) • BLK (BLK proto-oncogene, Src family tyrosine kinase)
    over1year
    Integrated multi-omics analysis of PBX1 in mouse adult neural stem- and progenitor cells identifies a transcriptional module that functionally links PBX1 to TCF3/4. (PubMed, Nucleic Acids Res)
    Introducing Pbx1 into Nalm6 cells, a pre-B cell line expressing TCF3 but lacking PBX1, upregulated the leukemogenic genes BLK and NOTCH3, arguing that functional PBX1-TCF cooperativity likely extends to hematopoiesis. Our study hence uncovers a transcriptional module orchestrating the balance between progenitor cell proliferation and differentiation in adult neurogenesis with potential implications for leukemia etiology.
    Preclinical • Journal
    |
    NOTCH3 (Notch Receptor 3) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1) • BLK (BLK proto-oncogene, Src family tyrosine kinase) • TCF4 (Transcription Factor 4)
    over2years
    Tyrosine phosphorylation of IRF3 by BLK facilitates its sufficient activation and innate antiviral response. (PubMed, PLoS Pathog)
    Subsequently, activated BLK directly binds and phosphorylates IRF3 at tyrosine 107, which further promotes TBK1-induced IRF3 S386 and S396 phosphorylation, facilitating sufficient IRF3 activation and downstream antiviral response. Collectively, our findings suggest that targeting BLK enhances viral clearance via specifically regulating IRF3 phosphorylation by a previously undefined mechanism.
    Journal
    |
    BLK (BLK proto-oncogene, Src family tyrosine kinase)
    over2years
    Comprehensive modular analyses of scar subtypes illuminate underlying molecular mechanisms and potential therapeutic targets. (PubMed, Int Wound J)
    The results necessitate further research to fully ascertain the roles of these identified genes and pathways in skin disease pathogenesis and potential therapeutics. Nonetheless, our work forms a strong foundation for a new era of personalised medicine for patients suffering from pathological scarring.
    Journal
    |
    TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1) • BLK (BLK proto-oncogene, Src family tyrosine kinase)
    over2years
    Discovery of promising B lymphocyte kinase inhibitors using structure-guided virtual screening. (PubMed, J Biomol Struct Dyn)
    The control molecule for this study was the known BLK inhibitor, Dasatinib...Both proposed molecules remained bound to the binding pocket of BLK, as indicated by the molecular dynamics (MD) simulation study. Taken together, these findings provide valuable insights for guiding future research endeavors and translational efforts in developing therapeutics for different complex diseases, such as autoimmune disorders, lymphomas, and leukemias.Communicated by Ramaswamy H. Sarma.
    Journal
    |
    BLK (BLK proto-oncogene, Src family tyrosine kinase)
    |
    dasatinib
    almost3years
    Loss of BLK expression as a potential predictor of poor prognosis and immune checkpoint blockade response in NSCLC and contribute to tumor progression. (PubMed, Transl Oncol)
    Our study provides strong evidence that low expression of BLK may serve as a biomarker for poor prognosis in NSCLC, while response to ICB therapy and contributes to NSCLC tumor progression.
    Journal • Checkpoint inhibition • IO biomarker • Checkpoint block
    |
    BLK (BLK proto-oncogene, Src family tyrosine kinase)
    over3years
    Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma. (PubMed, J Pathol Transl Med)
    Here, we describe the clinicopathological features and survival outcome according to expression of BLK in DLBCL. Approximately 39% of DLBCL patients showed BLK positivity, which was associated as a predictive marker for poor prognosis in patients who received R-CHOP chemotherapy.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • SYK (Spleen tyrosine kinase) • BLK (BLK proto-oncogene, Src family tyrosine kinase) • CDK1 (Cyclin-dependent kinase 1)
    |
    BCL2 expression • MYC expression
    |
    Rituxan (rituximab)
    almost4years
    An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy. (ESMO-BC 2022)
    In our cohort, the 8-gene signature as well as the RCB score were validated as independent prognostic factors in multivariate analysis.Conclusions Lack of immune activation after NACT is associated with a high risk of distant relapse. We propose a prognostic signature based on immune infiltrate that could help select patients in need of adjuvant therapies.
    Clinical • IO biomarker
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • BLK (BLK proto-oncogene, Src family tyrosine kinase) • CXCR6 (C-X-C Motif Chemokine Receptor 6) • SLAMF7 (SLAM Family Member 7)
    |
    nCounter® PanCancer IO 360™ Panel
    4years
    Whole-exome sequencing, EGFR amplification and infiltration patterns in human glioblastoma. (PubMed, Am J Cancer Res)
    On the other hand, mutations in ADGB, EHHADH, and PTPN13, were present only in the EGFR-no-amplified group with a more diverse infiltrative phenotype. Overall, our work identified different mutational portraits of GBM related to well-established features like EGFR amplification and tumor infiltration.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • BLK (BLK proto-oncogene, Src family tyrosine kinase)
    |
    EGFR mutation • EGFR amplification
    almost5years
    [VIRTUAL] Transcriptomic profiling of peripheral blood mononuclear cells in patients with multiple primary melanoma. (ASCO 2021)
    The GEP of PBMC's from PTs with MPM was similar overall to that of PTs with SPM/HC, with only a subset of genes exhibiting differentially expression in PTs with MPM vs . PTs with SPM and HCs . GEP varied in relation to Breslow thickness, stage, ulceration, and TIL content in MELs.
    Clinical
    |
    CD19 (CD19 Molecule) • TNFA (Tumor Necrosis Factor-Alpha) • CD22 (CD22 Molecule) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • SYK (Spleen tyrosine kinase) • CCL2 (Chemokine (C-C motif) ligand 2) • IL18 (Interleukin 18) • IRF1 (Interferon Regulatory Factor 1) • TBX21 (T-Box Transcription Factor 21) • GZMA (Granzyme A) • IFIT1 (Interferon Induced Protein With Tetratricopeptide Repeats 1) • BLK (BLK proto-oncogene, Src family tyrosine kinase) • CXCL3 (C-X-C Motif Chemokine Ligand 3)
    |
    IRF1 expression
    |
    nCounter® PanCancer Immune Profiling Panel